ArticleScientific reports2026
Prognostic effect of changes in high-density lipoprotein cholesterol after kidney transplantation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
High-density lipoprotein cholesterol (HDL-C) is inversely associated with cardiovascular diseases and may protect kidney function. This study evaluated the impact of early post-transplant HDL-C changes on clinical outcomes in kidney transplant recipients (KTRs). A total of 4,446 KTRs were classified into four groups according to HDL-C levels before transplantation and at 6 months post-transplant: low-low, low-normal, normal-low, and normal-normal. The primary outcome was a composite of cardiovascular events and graft failure. KTRs with persistently normal HDL-C levels had the lowest incidence of the composite outcome. Cox regression analysis revealed that persistent low HDL-C levels, improvement from low to normal HDL-C levels, and a decline from normal to low HDL-C levels showed an increased risk of the composite outcome compared to persistent normal HDL-C levels (HR, 1.48, 95% CI, 1.09-2.02, P=0.013; HR, 1.41, 95% CI, 1.10-1.80, P=0.006; and HR, 2.09, 95% CI, 1.35-3.24, P=0.001, respectively). Persistently low HDL-C levels and low-to-normal HDL-C changes were mainly associated with cardiovascular events, whereas post-transplant HDL-C decline was more strongly linked to graft failure. Abnormal HDL-C trajectories after kidney transplantation were significantly associated with unfavorable long-term cardiovascular and graft outcomes, highlighting the prognostic importance of both pre- and post-transplant HDL-C status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.